Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide for UV-induced DNA damage in healthy volunteers
NCT05368857Phase 1Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Afamelanotide in xeroderma pigmentosum (XP), sponsored by Clinuvel Pharmaceuticals. Primary endpoints: Change in UV photoproduct levels in UVR-exposed skin at Day 28 and Change in rate of UV photoproduct repair in UVR-exposed skin at Day 28. Started Jan 2022; status: completed.
02
Drugs
Afamelanotide
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on NCT05368857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368857.